S. Morimoto

发表

A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches

Z. Berneman, H. Sugiyama, Q. Lecocq, 2018, Oncotarget.

Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study

H. Eguchi, H. Nagano, M. Unno, 2018, Cancer Immunology Research.

Immune adjuvant therapy using Bacillus Calmette–Guérin cell wall skeleton (BCG-CWS) in advanced malignancies

I. Kawase, S. Morita, Toshinori Ito, 2019, Medicine.

Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response

T. Yoshimine, J. Sakamoto, S. Morita, 2015, Cancer Immunology, Immunotherapy.

Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides

N. Hosen, Y. Oji, A. Tsuboi, 2020, Cancer Immunology, Immunotherapy.

An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells

N. Hosen, Y. Oji, A. Tsuboi, 2016, Journal of immunotherapy.

Identification of a WT1 protein‐derived peptide, WT1187, as a HLA‐A*0206‐restricted, WT1‐specific CTL epitope

I. Kawase, N. Hosen, Y. Oji, 2008, Microbiology and immunology.

T Cell-Intrinsic Vitamin A Metabolism and Its Signaling Are Targets for Memory T Cell-Based Cancer Immunotherapy

M. Ikawa, N. Hosen, Y. Oji, 2021, bioRxiv.

Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms

N. Hosen, Y. Oji, A. Tsuboi, 2015, PloS one.

Glycosylation Status of CD43 Protein Is Associated with Resistance of Leukemia Cells to CTL-Mediated Cytolysis

N. Hosen, Y. Oji, A. Tsuboi, 2016, PloS one.

WT1 Peptide Vaccine for the Treatment of Malignancies: Its Development, Recent Progress, and Future Perspectives

N. Hosen, Y. Oji, A. Tsuboi, 2016 .

Biased usage of T cell receptor β‐chain variable region genes of Wilms’ tumor gene (WT1)‐specific CD8+ T cells in patients with solid tumors and healthy donors

T. Yoshimine, T. Enomoto, M. Sekimoto, 2012, Cancer Science.

Functional human Th17 clones with WT1-specific helper activity

N. Hosen, Y. Oji, A. Tsuboi, 2013, Cancer Immunology, Immunotherapy.

A Zbtb7a proto‐oncogene as a novel target for miR‐125a

N. Hosen, Y. Oji, A. Tsuboi, 2016, Molecular carcinogenesis.

WT1 peptide‐based immunotherapy for advanced thymic epithelial malignancies

J. Sakamoto, E. Morii, S. Morita, 2018, International journal of cancer.

An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia

K. Takeda, T. Shirakawa, A. Tsuboi, 2022, Cancer Immunology, Immunotherapy.

Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides

N. Hosen, Y. Oji, A. Tsuboi, 2018, Oncotarget.

HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T Lymphocytes Display a Helper Activity for WT1-specific CTL Induction and a Cytotoxicity Against Leukemia Cells

N. Hosen, Y. Oji, A. Tsuboi, 2013, Journal of immunotherapy.

Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration.

I. Kawase, N. Hosen, Y. Oji, 2012, Vaccine.

Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease

T. Kyo, N. Hosen, Y. Oji, 2012, Leukemia.

A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma

J. Sakamoto, S. Morita, N. Hosen, 2018, Cancer Immunology, Immunotherapy.

Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide

T. Yoshimine, J. Sakamoto, S. Morita, 2016, International journal of cancer.

Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain

K. Akashi, K. Takenaka, H. Kishima, 2022, Science Translational Medicine.

The activated conformation of integrin β7 is a novel multiple myeloma–specific target for CAR T cell therapy

T. Nakao, J. Takagi, K. Takeda, 2017, Nature Medicine.

WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1

H. Kishima, M. Ohmi, N. Naka, 2023, Cancers.

Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia

T. Shirakawa, A. Tsuboi, K. Ozono, 2023, BMC Cancer.

An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia

K. Takeda, T. Shirakawa, A. Tsuboi, 2022, Cancer Immunology, Immunotherapy.

Identification of mouse helper epitopes for WT1-specific CD4+ T cells

N. Hosen, Y. Oji, A. Tsuboi, 2021, Cancer Immunology, Immunotherapy.

Imaging Assessment of Tumor Response in the Era of Immunotherapy

J. Hatazawa, Y. Oji, A. Tsuboi, 2021, Diagnostics.

Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer

Y. Takeda, H. Eguchi, Y. Doki, 2014, Journal of immunotherapy.

Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine

K. Mizuguchi, N. Hosen, Y. Oji, 2016, Future science OA.

Two distinct effector memory cell populations of WT1 (Wilms’ tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients

Kenji Mizuguchi, Sumiyuki Nishida, Atsushi Kumanogoh, 2015, Cancer Immunology, Immunotherapy.

Transduction of a novel HLA-DRB1*04:05-restricted, WT1-specific TCR gene into human CD4+ T cells confers killing activity against human leukemia cells.

N. Hosen, Y. Oji, A. Tsuboi, 2015, Anticancer research.

In vivo eradication of MLL/ENL leukemia cells by NK cells in the absence of adaptive immunity

N. Hosen, Y. Oji, A. Tsuboi, 2014, Leukemia.

Wilms tumour 1 peptide vaccine as a cure‐oriented post‐chemotherapy strategy for patients with acute myeloid leukaemia at high risk of relapse

N. Hosen, Y. Oji, M. Kawakami, 2018, British journal of haematology.

An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells

N. Hosen, Y. Oji, A. Tsuboi, 2015, PloS one.

Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine

M. Hino, N. Hosen, Y. Oji, 2013, Blood Cancer Journal.

WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine

E. Morii, N. Naka, N. Hosen, 2022, Oncology letters.

Cellular and Humoral Immune Responses Induced by an HLA Class I–restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer

T. Enomoto, S. Morita, N. Hosen, 2021, Journal of immunotherapy.

Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs

Y. Oji, A. Tsuboi, Y. Oka, 2023, Cancer Immunology, Immunotherapy.

Establishment of a novel platform cell line for efficient and precise evaluation of T cell receptor functional avidity

Y. Nishida, N. Hosen, Y. Oji, 2018, Oncotarget.

Biased usage of T cell receptor β‐chain variable region genes of Wilms’ tumor gene (WT1)‐specific CD8+ T cells in patients with solid tumors and healthy donors

T. Yoshimine, T. Enomoto, M. Sekimoto, 2012, Cancer science.

The activated conformation of integrin β7 is a novel multiple myeloma–specific target for CAR T cell therapy

T. Nakao, J. Takagi, K. Takeda, 2017, Nature Medicine.

Enhancing the immunogenicity of Wilms tumor 1 epitope in mesothelioma cells with immunoproteasome inhibitors

F. Fujiki, S. Morimoto, S. Koido, 2024, PloS one.